Olivia Ng, PhD

Senior Medical Affairs Manager

Hong Kong SAR

About

Experience

  • Senior Medical Affairs Manager, Autoimmune & Neuroscience at Eli Lilly and Company
    Dec 2024 - Present · 1 yr 7 mos

  • Senior Manager, Medical Affairs at Gilead Sciences
    Apr 2022 - Dec 2024 · 2 yrs 9 mos

    - Lead the medical affairs tactics and develop brand strategies with cross-function teams for liver disease in the company - Support the medical affairs in the region including Hong Kong, Macau, Singapore, Malaysia and Brunei

  • Medical Lead, Alzheimer Disease at Biogen
    Dec 2021 - Apr 2022 · 5 mos

    - Conducted the site readiness assessment as well as localizing all the relevant documents for launching an early access program for an Alzheimer’s Disease product. - Established the local HCP profile in the disease area and setting up the base for future pre-launch activities (HK position was eliminated in April 2022)

  • Merck Group (Full-time · 3 yrs 10 mos)
    • Head of Medical Affairs
      Jun 2020 - Dec 2021 · 1 yr 7 mos

      - Deputy of MD - Engaged with internal colleagues (Legal and Compliance, Clinical Operations and Commercial colleagues as appropriate, etc.) in developing, delivering and participating in Medical and/or cross-functional initiatives - Supported the medial team re-structure and led a team with 3 MSLs - Supervised the team in executing the medical tactics along with defined Medical launch/asset strategies and plans, and managed the budget across all TA included, Neuro-immunology, Oncology, Fertility, Endocrinology and General Medicine in Hong Kong

    • Medical Science Liaison
      Mar 2018 - May 2020 · 2 yrs 3 mos

      Responsible for the products in Neuro-immunology franchise (DMD for multiple sclerosis) and Oncology franchise (target therapy for mCRC, SCCHN and NSCLC). Participate in strategic planning for launching and existing products.

  • Medical Affairs Associate at Daiichi Sankyo, Inc.
    Sep 2016 - Mar 2018 · 1 yr 7 mos

    Responsible for a CV product, engaged with KOLs in multi-specialties (include cardiology, haematology and neurology), participated in strategic planning and rolled out the projects for launching a new product, engaged and initiated 6 study sites in HK for a global observational study.